… erlotinib with gefitinib in preventing and controlling brain metastases in NSCLC patients
harboring EGFR-sensitive mutations. The aim of this retrospective study is to … of any retrospective …

… gefitinib and icotinib as second-line treatment, and three patients received both gefitinib and
erlotinib … This multi-center study involved retrospective analysis. All patients were diagnosed …

… The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly …
receptor (EGFR) mutations were analyzed retrospectively. We analyzed chemotherapy-naïve …

… Herein, we present the results of our retrospective analysis data to evaluate the survival
benefit of first-line EGFR-TKI therapy, as compared to that of cytotoxic chemotherapy or best …

… The studies included in this review used standard treatment protocols for gefitinib and erlotinib,
ie., 250 mg/d and 150 mg/d … A retrospective study analysed 14 patients who had received …

Background Median PFS in the key phase III trials with gefitinib or erlotinib for advanced
NSCLC with EGFR sensitizing mutations was less than 12 months. There are only a few data …

… confirmed by another recent retrospective study based on a … , one phase III trial evaluated
the adjuvant use of gefitinib in … Another randomized, phase II, open-label, multicenter study (…

… effectiveness and safety of afatinib, gefitinib, and erlotinib for elderly patients with epidermal
… , this study aimed to describe the effectiveness and safety of afatinib, gefitinib, and erlotinib …

… trial with erlotinib as second-line treatment versus docetaxel or pemetrexed (Tarceva in
Treatment of Advanced NSCLC [TITAN study]). … In summary, this retrospective study showed that …

… were included in this retrospective multicentric data analysis (… in this study actually had
poorer outcomes with gefitinib (hazard … is more cost effective than erlotinib, further information is …